Home Ingredients AHCC (Active Hexose Correlated Compound)
Immune SupportWomen's Health

AHCC (Active Hexose Correlated Compound)

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

AHCC is a proprietary fermented mushroom mycelium extract — primarily from shiitake (Lentinula edodes) and other basidiomycetes — developed by Amino Up Co. (Japan) since 1989. Distinguished from whole mushroom extracts by acetylated alpha-glucan (rather than typical beta-glucan) as primary active. Researched mainly for immune support, including studies of the immune response in women with persistent HPV and use alongside conventional care. Substantial clinical research base for a mushroom-derived supplement.

Studied Dose 1-3 g/day; 3 g/day for 6 months in the HPV immune-support trials (Smith 2022 phase 2 RCT); 1-3 g/day for immune support
Active Compound Alpha-glucan oligosaccharides (acetylated; ~20% of extract); other polysaccharides

Benefits

Immune Support in Women with Persistent HPV

In a phase 2 randomized, double-blind, placebo-controlled trial in 50 women with high-risk HPV persisting over 2 years (41 completed), 14 of 22 women taking AHCC 3 g/day were HPV negative at 6 months and 9 were still negative 6 months after stopping, versus 2 of 19 on placebo. Two earlier open-label pilots of about 10 women each pointed the same way. This is a single small trial, and the lead author had prior research grants from the maker, so it is early evidence that AHCC may support the immune response to HPV, not proof that it clears an infection.

Supported by Trial 1

Immune and Well-Being Support During Conventional Care

Some Japanese studies in people receiving cancer treatment, mostly non-randomized cohorts, have reported better self-rated quality of life and fewer side effects. These are small, non-randomized, and industry-linked. AHCC is not a cancer treatment and should not be expected to change the course of any cancer; anyone in treatment should use it only with their oncologist's knowledge.

Supported by Trial 2, Trial 1

Immune Cell Activation

In a controlled trial in healthy volunteers, AHCC 3 g/day raised the number and function of dendritic cells (antigen-presenting immune cells). The same trial found no significant change in NK cell activity, T-cell response, or cytokine production, so the common claim of NK activation is not well supported in humans. These are immune-marker (laboratory) changes, not a measured clinical outcome.

Supported by Trial 1

Liver Markers (Limited, Preliminary Evidence)

Evidence here is limited and preliminary. A few small studies have looked at liver-enzyme markers during medical treatment, but this is not an established benefit and AHCC should not be used to treat any liver disease, including viral hepatitis.

Supported by Trial 2, Trial 1

General Immune Support

This is general immune-support research only. AHCC is not a treatment for influenza, HIV, or any infection, and should not be used in place of medical care for an infection.

Supported by Trial 1

Mechanism of action

1

Acetylated Alpha-Glucan Active

AHCC's distinctive feature is acetylated alpha-glucan oligosaccharides (~20% of extract) — different from typical mushroom beta-glucans (lentinan, MD-fraction, etc.). Theoretical advantage: alpha-glucan oligosaccharides may have better oral absorption than complex beta-glucan polymers.

2

NK Cell Activation

AHCC is often described as increasing natural killer (NK) cell activity. The main controlled human trial, however, found no significant change in NK activity, and NK activation rests more on laboratory and animal work than on human trials. Dendritic-cell effects are the more consistent human finding.

3

Dendritic Cell Function

Activates dendritic cells — antigen-presenting cells that bridge innate and adaptive immunity. Important for sustained immune responses.

4

Cytokine Modulation

Modulates inflammatory cytokine balance — typically increases Th1 (cellular immunity) cytokines while modulating inflammatory response. Different from indiscriminate immune stimulation.

Clinical trials

1
AHCC and the Immune Response to Persistent HPV (Phase 2 RCT)
PubMed

Randomized, double-blind, placebo-controlled phase 2 trial (NCT02405533) of AHCC 3 g/day for 6 months in 50 women over 30 with high-risk HPV persisting more than 2 years; 41 completed. Run at UT Health, Houston. The lead author previously received research grants from the maker.

50 women with persistent high-risk HPV infection (41 completed).

14 of 22 women taking AHCC were HPV negative at 6 months, and 9 were still negative 6 months after stopping, versus 2 of 19 on placebo. A single small trial with industry ties: early support that AHCC may aid the immune response to HPV, not proof that it clears an infection.

2
AHCC in Liver Cancer Patients (Non-Randomized Cohort)
PubMed

Non-randomized prospective cohort of AHCC in patients after surgery for hepatocellular carcinoma (Matsui 2002, J Hepatol), plus similar Japanese cohorts. No placebo control, and treatment was not randomized.

Patients after surgery for hepatocellular carcinoma.

The cohort reported longer recurrence-free and overall survival in AHCC users versus non-users, but treatment was chosen rather than randomized, so it cannot show AHCC caused the difference. AHCC is not a cancer treatment.

Side effects and drug interactions

Common Potential side effects

Generally very well-tolerated.
Mild GI distress (nausea, diarrhea, gas) — particularly during initial use.
Headache rare.
Allergic reactions to mushroom rare.
Caution in autoimmune disease (theoretical immune activation concern).
Avoid in transplant patients without medical supervision.

Important Drug interactions

Chemotherapy — used adjunctively in Japan; consult oncologist for specific regimens.
Immunosuppressants — avoid in transplant patients without medical supervision; immune activation opposes intentional immunosuppression.
Anticoagulants — theoretical minor bleeding risk.
Other immune-modulating supplements — additive effects.
CYP3A4 substrates — potentially modest effects (limited data).

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble essential nutrient that humans cannot synth…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Immune Support
Zinc Acetate
Zinc acetate is zinc bound to acetic acid, a well-absorbed form that is among the best stu…
Immune Support
Bioferrin® (Lactoferrin — Glanbia)
Bioferrin® is a lactoferrin ingredient from Glanbia — distinguished by milk-derived lactof…

Explore Other Ingredients

Antioxidant
Alpha Lipoic Acid
Alpha-lipoic acid (ALA) is a versatile antioxidant made naturally in the body that is unus…
Antioxidant
Milk Thistle
Milk thistle, from the Silybum marianum plant, contains silymarin, a group of plant compou…
Antioxidant
Dandelion Root
Dandelion root is a traditional herb used to support liver and digestive health and as a g…

Frequently asked questions about AHCC (Active Hexose Correlated Compound)

What is AHCC?

AHCC (Active Hexose Correlated Compound) is a standardized extract made from the mycelia of shiitake and other mushrooms, rich in alpha-glucans. It is one of the most studied mushroom-derived immune supplements, popular for immune support.

What is AHCC used for?

It is used mainly for immune support, with research including its use alongside conventional care and studies on supporting the body's response to certain viral challenges (such as HPV). Its alpha-glucans are thought to support immune-cell activity.

How much AHCC should I take?

Studies commonly use about 1 to 3 grams per day, often taken on an empty stomach. Follow the specific product's labeling, as AHCC is a standardized ingredient.

Is AHCC safe?

AHCC has a good safety record in studies and is generally well tolerated; mild digestive upset can occur. Those on immune-modulating medication or undergoing treatment should use it with their doctor's knowledge.

What is the recommended dosage of AHCC?

The clinically studied dose is 1-3 g/day; 3 g/day for 6 months in the HPV immune-support trials (Smith 2022 phase 2 RCT); 1-3 g/day for immune support Always follow the product label and check with a healthcare provider for personal advice.

Is AHCC safe, and does it have side effects?

For most healthy adults, AHCC is well tolerated at studied doses. Reported effects can include: Generally very well-tolerated. Mild GI distress (nausea, diarrhea, gas) — particularly during initial use. It may also interact with some medications. AHCC is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does AHCC interact with any medications?

Possible interactions include: Chemotherapy — used adjunctively in Japan; consult oncologist for specific regimens. Immunosuppressants — avoid in transplant patients without medical supervision; immune activation opposes intentional immunosuppression. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for AHCC?

NutraSmarts rates the evidence for AHCC as Limited (2 out of 5). It is backed by 2 clinical trials and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer. 2008;60(5):643-51. doi: 10.1080/01635580801993280.PubMedUsed to support: Double-blind RCT in 21 healthy volunteers in which AHCC 3 g/day increased the number and function of dendritic cells but produced no significant change in NK cell activity, T-cell response, or cytokine production. The main controlled human trial behind the immune-support use, and an immune-marker result rather than a clinical outcome.
  2. Smith JA, Gaikwad AA, Mathew L, Rech B, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT. AHCC(®) Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. Front Oncol. 2022;12:881902. doi: 10.3389/fonc.2022.881902.PubMedUsed to support: Clinical study of AHCC supplementation supporting immune clearance of persistent high-risk HPV infection. Supports the immune and women's-health uses, though larger trials are still needed.
  3. Smith JA, Mathew L, Gaikwad A, Rech B, Burney MN, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT. From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Front Oncol. 2019;9:173. doi: 10.3389/fonc.2019.00173.PubMedUsed to support: Bench-to-bedside pilot evaluating AHCC to modulate host immunity and clear persistent HPV. Early human support for the HPV and immune use.
  4. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother. 2006;55(10):1258-66. doi: 10.1007/s00262-005-0111-9.PubMedUsed to support: Preclinical study showing AHCC enhances tumor immune surveillance through both innate and adaptive immunity. Mechanistic background only; this is laboratory evidence, not a human outcome.
  5. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37(1):78-86. doi: 10.1016/s0168-8278(02)00091-0.PubMedUsed to support: Non-randomized prospective cohort in patients after surgery for hepatocellular carcinoma, reporting longer recurrence-free and overall survival in those who took AHCC versus those who did not. Because treatment was chosen rather than randomized, it cannot establish that AHCC caused the difference.